Treatment of cryptosporidiosis with spiramycin in AIDS. An N of 1 trial. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment of cryptosporidiosis with spiramycin in AIDS. An N of 1 trial.

J Clin Gastroenterol. 1987 Dec;9(6):632-4. Unique Identifier : AIDSLINE MED/88170642
Woolf GM; Townsend M; Guyatt G; McMaster University Medical Center, Department of Medicine,; Hamilton Ontario, Canada.

Abstract: We describe a randomized, double-blind, placebo-controlled, crossover trial with spiramycin in a single patient with acquired immune deficiency syndrome (AIDS) and a severe secretory diarrhea caused by cryptosporidium. Spiramycin, a potentially harmful antibiotic, had no clinical or microbiological effect in this patient. The application of the single patient (N of 1) trial to common clinical problems is a simple way to analyze the value of different therapeutic approaches. The time-consuming, expensive, multi-patient trial with ultimate extrapolation to the individual patient can be avoided. Single-patient trials can influence management and improve patient care and have potentially wide use in patients with gastrointestinal disease.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Case Report Clinical Trials Cryptosporidiosis/COMPLICATIONS/*DRUG THERAPY/ETIOLOGY Diarrhea/ETIOLOGY Double-Blind Method Human Leucomycins/*THERAPEUTIC USE Male Random Allocation CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationsadultcasereportclinicaltrialscryptosporidiosis/complications/KWDdrugtherapy/etiologydiarrhea/etiologydouble-blindmethodhumanleucomycins/KWDtherapeuticusemalerandomallocationclinicaltrialjournalarticlerandomizedcontrolledtrial
880730
M8870436

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .